Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Summary

The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part.

Timeline

Start

2015-04-21

Primary completion

2018-09-14

Completion

2022-02-10

Drugs

Indications